The U.S. Food and Drug Administration has approved the first immunotherapy drug for breast cancer.

Continue Reading Below

Swiss drugmaker Roche’s Tecentriq was OK’d Friday for treating advanced triple-negative breast cancer, which accounts for about 15 percent of cases. It’s to be given with chemotherapy, the standard treatment.